Latest News From "The Pink Sheet" DAILY

ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon

A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C. read_more_>

 

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion. read_more_>

 

Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK

Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK. read_more_>

 

Should FDA Warning Letter Prompt Securities Suit? Government, PhRMA Disagree

Supreme Court is to decide when Merck investors had sufficient information to sue for securities fraud; FDA warning letter about Vioxx risks is at issue. read_more_>

 

California Stem Cell Agency: "Valley of Death" Cash Will Get Treatments To Clinic

But biotechs shouldn't expect salvation, as an anticipated loan program is off to a slow start. read_more_>